🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

129 results for “intravenous” Clear

  1. 0.9% w/v sodium chloride solution for intravenous infusion, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  2. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  5. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  6. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  7. Immune Globulin 10% Intravenous Solution

    Vera Therapeutics

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  8. Immune Globulin Intravenous (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  9. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  10. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  11. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  12. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

  13. Immune Globulin Intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  14. Immune Globulin Intravenous (human), 10%

    Takeda

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  15. Immunoglobulins, Intravenous (Privigen)

    United Therapeutics Europe Ltd

    Encephalitis

    phase 3 small molecule completed

    1 trial

  16. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial

  17. Intravenous Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Postoperative Pain

    phase 3 small molecule active

    1 trial

  18. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  19. Intravenous Methylprednisolone

    Cardiff Oncology

    Myelitis, Transverse

    phase 3 small molecule terminated

    1 trial

  20. Intravenous ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Tonsillectomy

    phase 3 small molecule completed

    1 trial

  21. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  22. Intravenous nicardipine hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule terminated

    1 trial

  23. Intravenous rhTNK-tPA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke, Acute Ischemic

    phase 3 small molecule active

    1 trial

  24. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources